Serizawa Fukashi, Sasaki Shigeru, Fujishima Shinobu, Akamatsu Daijirou, Goto Hitoshi, Amada Noritoshi
Department of Vascular Surgery, Japan Community Health Care Organization Sendai Hospital, Sendai, Japan.
Department of Vascular Surgery, Japan Community Health Care Organization Sendai Hospital, Sendai, Japan.
J Vasc Surg. 2016 Oct;64(4):1018-25. doi: 10.1016/j.jvs.2016.03.452. Epub 2016 May 14.
The number of hemodialysis patients with peripheral artery disease is increasing, and critical limb ischemia develops in some of these patients. The clinical outcomes in such patients after major amputation remain unclear. We therefore examined the mortality rates after major amputation in hemodialysis patients.
The study enrolled 108 hemodialysis patients undergoing their first major amputation at Community Health Care Organization Sendai Hospital between January 2005 and December 2014 and monitored them until June 2015. All-cause mortality and additional amputation-free survival were evaluated by Kaplan-Meier analysis.
The most dominant primary disease of renal failure was diabetes mellitus (77%), and the duration of hemodialysis was 8.5 ± 6.8 years. During the median follow-up period of 11.5 months (20.3 ± 22.6 months), 80 patients (74%) died, and the survival rates were 83% at 30 days, 56% at 1 year, and 15% at 5 years. The median time to death was 19.9 months (95% confidence interval, 9.8-30.0 months), and the causes of death were cardiac (45%), sepsis (29%), cerebrovascular (4%), and others (22%). Thirty-one patients underwent additional amputation, and the additional amputation-free survival rates were 39% at 1 year and 9% at 5 years. The median time between the first and second amputations was 2.5 months (5.7 ± 7.6 months). Univariate analysis showed previous minor amputation (P = .04) and low hematocrit level (P = .04) were associated with the 30-day mortality rate, and age (P = .05) was associated with the 5-year mortality rate. On multivariate Cox proportional hazard analysis, only age was associated with mortality rate (hazard ratio, 1.02; 95% confidence interval, 0.99-1.02; P = .04). We also compared walking ability before and after major amputation among patients who survived >60 days. The rate changed from 34% to 12% for of ambulatory patients, from 45% to 48% for wheelchair use, and from 21% to 40% for bedridden patients. Ambulatory patients had a significantly better survival rate than the others (P = .02).
The mortality rate after major amputation in hemodialysis patients was high, and major amputation had a huge negative effect on patients' walking ability.
患有外周动脉疾病的血液透析患者数量正在增加,其中一些患者会发展为严重肢体缺血。这些患者接受大截肢术后的临床结局仍不明确。因此,我们研究了血液透析患者大截肢术后的死亡率。
本研究纳入了2005年1月至2014年12月期间在仙台市社区医疗保健组织医院首次接受大截肢手术的108例血液透析患者,并对他们进行监测直至2015年6月。通过Kaplan-Meier分析评估全因死亡率和无再次截肢生存率。
肾衰竭最主要的原发性疾病是糖尿病(77%),血液透析时长为8.5±6.8年。在11.5个月(20.3±22.6个月)的中位随访期内,80例患者(74%)死亡,30天时的生存率为83%,1年时为56%,5年时为15%。中位死亡时间为19.9个月(95%置信区间,9.8 - 30.0个月),死亡原因包括心脏疾病(45%)、败血症(29%)、脑血管疾病(4%)和其他原因(22%)。31例患者接受了再次截肢,1年时的无再次截肢生存率为39%,5年时为9%。首次与第二次截肢之间的中位时间为2.5个月(5.7±7.6个月)。单因素分析显示,既往小截肢(P = .04)和低血细胞比容水平(P = .04)与30天死亡率相关,年龄(P = .05)与5年死亡率相关。多因素Cox比例风险分析显示,只有年龄与死亡率相关(风险比,1.02;95%置信区间,0.99 - 1.02;P = .04)。我们还比较了存活超过60天的患者大截肢前后的行走能力。能行走的患者比例从34%降至12%,使用轮椅的患者比例从45%升至48%,卧床患者比例从21%升至40%。能行走的患者生存率显著高于其他患者(P = .02)。
血液透析患者大截肢术后死亡率较高,且大截肢对患者的行走能力有巨大负面影响。